Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹36,808 Cr
Revenue (TTM)
₹5,202 Cr
Net Profit (TTM)
₹1,015 Cr
ROE
25.1 %
ROCE
32.9 %
P/E Ratio
36.3
P/B Ratio
8
Industry P/E
28.7
EV/EBITDA
24.8
Div. Yield
1 %
Debt to Equity
0
Book Value
₹367.3
EPS
₹81.2
Face value
2
Shares outstanding
124,935,624
CFO
₹5,920.26 Cr
EBITDA
₹8,324.62 Cr
Net Profit
₹5,936.84 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ajanta Pharma
| 6.3 | -0.6 | 13.2 | 13.1 | 36.0 | 19.9 | 12.6 |
|
BSE Healthcare
| -4.0 | -3.8 | -4.0 | 3.0 | 24.6 | 15.5 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ajanta Pharma
| -7.5 | 35.8 | 71.9 | -18.7 | 35.4 | 66.9 | -17.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ajanta Pharma
|
2,943.9 | 36,807.9 | 5,201.6 | 1,014.6 | 22.9 | 25 | 36.3 | 8.0 |
| 8,370.5 | 20,886.1 | 2,177.5 | 200.9 | 11.3 | 26.5 | 104 | 25.1 | |
| 1,621.8 | 12,325.3 | 2,089.5 | 622.0 | 31.3 | 20.4 | 20.1 | 3.7 | |
| 1,286.2 | 17,770.9 | 3,078.2 | 469.4 | 26.4 | 14.9 | 41.2 | 4.9 | |
| 2,084.9 | 33,478.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 44.4 | 8.4 | |
| 4,724.5 | 21,607.1 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.3 | 5.4 | |
| 4,819.4 | 8,003.6 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27.3 | 11.5 | |
| 3,408.1 | 7,850.1 | 1,837.4 | 326.7 | 24.7 | 45.3 | 24 | 10.5 | |
| 314.8 | 6,154.0 | 1,432.0 | 149.0 | 19.1 | 7.9 | 41 | 2.5 | |
| 897.6 | 8,271.1 | 4,725.6 | 528.7 | 14.9 | 20.7 | 16.2 | 2.8 |
1 min read•By Research Desk
2 min read•By Value Research
Is your company's RoCE rising every year?
1 min read•By Vikas Vardhan
2 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque
1 min read•By Research Desk
Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such... as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India. Read more
Incorporated
1979
Chairman
Mannalal B Agrawal
Managing Director
Yogesh M Agrawal
Group
Vimal Agrawal
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Ajanta Pharma Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsParticipation In Investor Conference
09-Mar-2026Rumour verification - Regulation 30(11)
10-Feb-2026Participation In Investor Conference
02-Feb-2026
The share price of Ajanta Pharma Ltd is ₹2,943.90 (NSE) and ₹2,946.15 (BSE) as of 19-Mar-2026 IST. Ajanta Pharma Ltd has given a return of 35.96% in the last 3 years.
The P/E ratio of Ajanta Pharma Ltd is 36.28 times as on 19-Mar-2026, a 26 premium to its peers’ median range of 28.70 times.
The P/B ratio of Ajanta Pharma Ltd is 8.02 times as on 19-Mar-2026, a 75 premium to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
35.53
|
8.64
|
|
2024
|
34.52
|
7.91
|
|
2023
|
25.89
|
4.49
|
|
2022
|
14.45
|
4.73
|
|
2021
|
15.82
|
5.18
|
The 52-week high and low of Ajanta Pharma Ltd are Rs 3,228.00 and Rs 2,327.30 as of 19-Mar-2026.
Ajanta Pharma Ltd has a market capitalisation of ₹ 36,808 Cr as on 19-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Ajanta Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-112.70
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.